The gefitinib-resistant lung cancer cell line (PC9GR) is established from its parental sensitive line (PC9) with a traditional EGFR mutation after long time exposure to gefitinib, which shows a quite different transcription, signaling, and metabolic profiles [55]. This evidence concerns the gene EGFR and lung cancer.